Evaluation of the relation between consumption of fluoroquinolones and emergence of resistance among Escherichia coli: Contribution of observational and quasi-experimental studies;Évaluation de la relation consommation de fluoroquinolones et émergence de résistance chez Escherichia coli: Rôles respectif et comparatif des études observationnelles et quasi expérimentales

Medecine et Maladies Infectieuses

Volumn 35, Issue 11, 2005, Pages 543-548

  Mahamat, A ^a,b   Daures J P ^a,b   Sotto, A ^b  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Escherichia coli; Fluoroquinolones; Quasi experimental study; Resistance

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; DISEASE ASSOCIATION; ESCHERICHIA COLI; EVALUATION; MEDICAL ETHICS; NONHUMAN; CASE CONTROL STUDY; COHORT ANALYSIS; DRUG EFFECT; DRUG UTILIZATION; HUMAN; REVIEW; STATISTICS;

CASE-CONTROL STUDIES; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI; FLUOROQUINOLONES; HUMANS;

EID: 29244479516     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2005.06.007     Document Type: Article

References (39)

1. E.F. Hendershot Fluoroquinolones Infect. Dis. Clin. North Am. 9 3 1995 715 730
2. K.G. Naber Treatment options for acute uncomplicated cystitis in adults J. Antimicrob. Chemother. 46 Suppl A 2000 23 27
3. D.A. Talan Clinical perspectives on new antimicrobials: focus on fluoroquinolones Clin. Infect. Dis. 32 Suppl 1 2001 S64 S71
4. A. Cometta, T. Calandra, J. Bille, and M.P. Glauser Escherichia:coli resistant to fluoroquinolones in patients with cancer and neutropenia N. Engl. J. Med. 330 17 1994 1240 1241
5. K. Gupta, T.M. Hooton, and W.E. Stamm Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections Ann. Intern. Med. 135 1 2001 41 50
6. J. Ena, M.M. Lopez-Perezagua, C. Martinez-Peinado, M.A. Cia-Barrio, and I. Ruiz-Lopez Emergence of ciprofloxacin resistance in Escherichia:coli isolates after widespread use of fluoroquinolones Diagn. Microbiol. Infect. Dis. 30 2 1998 103 107
7. J. Sirot, M.H. Nicolas-Chanoine, H. Chardon, J.L. Avril, C. Cattoen, and J.C. Croix Susceptibility of Enterobacteriaceae to beta-lactam agents and fluoroquinolones: a 3:years survey in France Clin. Microbiol. Infect. 8 4 2002 207 213
8. M. Sorberg, A. Farra, U. Ransjo, B. Gardlund, M. Rylander, and B. Settergren Different trends in antibiotic resistance rates at a university teaching hospital Clin. Microbiol. Infect. 9 5 2003 388 396
9. W. Goettsch, W. van Pelt, N. Nagelkerke, M.G. Hendrix, A.G. Buiting, and P.L. Petit Increasing resistance to fluoroquinolones in Escherichia:coli from urinary tract infections in the Netherlands J. Antimicrob. Chemother. 46 2 2000 223 228
10. J.H. Yoo, D.H. Huh, J.H. Choi, W.S. Shin, M.W. Kang, and C.C. Kim Molecular epidemiological analysis of quinolone-resistant Escherichia:coli causing bacteremia in neutropenic patients with leukemia in Korea Clin. Infect. Dis. 25 6 1997 1385 1391
11. H.N. Canawati, R. el-Farra, J. Seymour, J. Shimashita, D. Dunn, and J.Z. Montgomerie Ciprofloxacin-resistant Escherichia:coli emerging in a rehabilitation medical center Diagn. Microbiol. Infect. Dis. 29 3 1997 133 138
12. D.N. Gilbert, S.J. Kohlhepp, K.A. Slama, G. Grunkemeier, G. Lewis, and R.J. Dworkin Phenotypic resistance of Staphylococcus:aureus, selected Enterobacteriaceae, and Pseudomonas:aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin Antimicrob. Agents Chemother. 45 3 2001 883 892
13. M. Watanabe, Y. Kotera, K. Yosue, M. Inoue, and S. Mitsuhashi In vitro emergence of quinolone-resistant mutants of Escherichia:coli, Enterobacter:cloacae, and Serratia:marcescens Antimicrob. Agents Chemother. 34 1 1990 173 175
14. Robert J. Fluoroquinolones et entérobactéries résistantes aux fluoroquinolones dans la flore digestive. In: Journées nationales d'infectiologie; 2003; Lille; 2003.
15. P. Richard, M.H. Delangle, F. Raffi, E. Espaze, and H. Richet Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant Gram-negative bacilli from gastrointestinal flora Clin. Infect. Dis. 32 1 2001 162 166
16. S. Harbarth, A.D. Harris, Y. Carmeli, and M.H. Samore Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli Clin. Infect. Dis. 33 9 2001 1462 1468
17. C. Pena, J.M. Albareda, R. Pallares, M. Pujol, F. Tubau, and J. Ariza Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia:coli in bloodstream infections Antimicrob. Agents Chemother. 39 2 1995 520 524
18. J. Garau, M. Xercavins, M. Rodriguez-Carballeira, J.R. Gomez-Vera, I. Coll, and D. Vidal Emergence and dissemination of quinolone-resistant Escherichia:coli in the community Antimicrob. Agents Chemother. 43 11 1999 2736 2741
19. L.C. McDonald, F.J. Chen, H.J. Lo, H.C. Yin, P.L. Lu, and C.H. Huang Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia:coli in Taiwan and contributions of distinct selective pressures Antimicrob. Agents Chemother. 45 11 2001 3084 3091
20. D. Lepelletier, N. Caroff, A. Reynaud, and H. Richet Escherichia:coli: epidemiology and analysis of risk factors for infections caused by resistant strains Clin. Infect. Dis. 29 3 1999 548 552
21. E.A. Gimber, M.D. Shields, H.N. Canawati, F.L. Sapico, A. Krishnaswamy, and R. El-Farra Bacteriuria with Escherichia:coli resistant to ciprofloxacin in patients with spinal-cord injury Infect. Control Hosp. Epidemiol. 19 2 1998 85 86
22. M.K. Bolon, S.B. Wright, H.S. Gold, and Y. Carmeli The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia:coli and Klebsiella:pneumoniae may be lower than previously reported Antimicrob. Agents Chemother. 48 6 2004 1934 1940
23. A.D. Harris, T.B. Karchmer, Y. Carmeli, and M.H. Samore Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review Clin. Infect. Dis. 32 7 2001 1055 1061
24. WHO Anatomical Therapeutic Chemical classification index with Define Daily Doses 2000 World Health Organization collaborating center for Drugs Statistics Methodology Oslo
25. L.V. Friedrich, R.L. White, and J.A. Bosso Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes Clin. Infect. Dis. 28 5 1999 1017 1024
26. M. Cizman, A. Orazem, V. Krizan-Hergouth, and J. Kolman Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia:coli from urinary tract infections J. Antimicrob. Chemother. 47 4 2001 502
27. G. Box, and G. Jenkins Time series analysis: forecasting and control 1976 Holden Day San Francisco, CA
28. A. Pankratz Forecasting with dynamic regression models 1991 Wiley New York, NY
29. J.M. Lopez-Lozano, D.L. Monnet, A. Yague, A. Burgos, N. Gonzalo, and P. Campillos Modelling and forecasting antimicrobial resistance and its dynamic relationship to antimicrobial use: a time series analysis Int. J. Antimicrob. Agents 14 1 2000 21 31
30. A. Mahamat, J. Lavigne, P. Fabbro-Peray, J. Kinowski, J. Daures, and A. Sotto Evolution of fluoroquinolone resistance among Escherichia:coli isolates from urinary tract in a French University Hospital: application of the dynamic regression model Clin. Microbiol. Infect. 11 4 2005 301 306
31. P. Berger, L. Pascal, C. Sartor, J. Delorme, P. Monge, and C.P. Ragon Generalized additive model demonstrates fluoroquinolone use-resistance relationships for Staphylococcus:aureus Eur. J. Epidemiol. 19 5 2004 453 460
32. F. Ansari, K. Gray, D. Nathwani, G. Phillips, S. Ogston, and C. Ramsay Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis J. Antimicrob. Chemother. 52 5 2003 842 848
33. Charbonneau P. Impact of fuoroquinolone restriction on MRSA, Caen University Hospital, 2001. In: ICAAC; 2003; Chicago, IL; 2003.
34. S. Greenland, and H. Morgenstern Ecological bias, confounding, and effect modification Int. J. Epidemiol. 18 1 1989 269 274
35. E. Perez-Trallero, M. Urbieta, D. Jimenez, J.M. Garcia-Arenzana, and G. Cilla Ten-year survey of quinolone resistance in Escherichia:coli causing urinary tract infections Eur. J. Clin. Microbiol. Infect. Dis. 12 5 1993 349 351
36. A. Sotto, C.M. De Boever, P. Fabbro-Peray, A. Gouby, D. Sirot, and J. Jourdan Risk factors for antibiotic-resistant Escherichia:coli isolated from hospitalized patients with urinary tract infections: a prospective study J. Clin. Microbiol. 39 2 2001 438 444
37. D.M. Livermore, A.P. Macgowan, and M.C. Wale Surveillance of antimicrobial resistance. Centralised surveys to validate routine data offer a practical approach BMJ 317 7159 1998 614 615
38. J.W. Warren, E. Abrutyn, J.R. Hebel, J.R. Johnson, A.J. Schaeffer, and W.E. Stamm Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA) Clin. Infect. Dis. 29 4 1999 745 758
39. B. Schlemmer Comment aḿliorer la qualit́ de l'antibioth́rapie dans les ́tablissements de soins:? Qualit́ ́gale pŕserver l'int́r̂t collectif sans nuire ̀ l'int́r̂t individuel du patient Med. Mal. Infect. 33 11 2003 593 610